Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6301 to 6315 of 7691 results

  1. COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)

    This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).

    Evidence summary: COVID-19 rapid summary
    Published
    29 June 2020

  2. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Evidence summary: COVID-19 rapid summary
    Published
    15 January 2021

  3. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Evidence summary: COVID-19 rapid summary
    Published
    20 January 2021

  4. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Evidence summary
    Published
    29 September 2015

  5. Postural hypotension in adults: midodrine (ESUOM5)

    This evidence summary has been updated and replaced by NICE evidence summary: new medicines 61.

    Evidence summary
    Published
    5 February 2013

  6. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Evidence summary
    Published
    5 January 2016

  7. Pulmonary hypertension in neonates: sildenafil (ESUOM51)

    This evidence summary has been withdrawn following updated information in the summary of product characteristics on the off-label use of sildenafil (Revatio) in neonates with persistent pulmonary hypertension of the newborn.

    Evidence summary
    Published
    29 March 2016

  8. Systemic lupus erythematosus: oral mycophenolate (ESUOM36)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Evidence summary
    Published
    18 November 2014

  9. Cystic fibrosis: long-term azithromycin (ESUOM37)

    This evidence summary has been updated and replaced by NICE guideline NG78.

    Evidence summary
    Published
    25 November 2014

  10. Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Evidence summary
    Published
    25 November 2014

  11. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Evidence summary
    Published
    10 March 2015

  12. Management of aggression, agitation and behavioural disturbances in dementia: valproate preparations (ESUOM41)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Evidence summary
    Published
    10 March 2015

  13. Scleroderma: oral mycophenolate (ESUOM32)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Evidence summary
    Published
    29 July 2014

  14. Interstitial cystitis: oral pentosan polysulfate sodium (ESUOM43)

    This guidance has been updated and replaced by NICE technology appraisal guidance 610.

    Evidence summary
    Published
    21 April 2015

  15. Rapid tranquillisation in mental health settings: promethazine hydrochloride (ESUOM28)

    This evidence summary has been updated and replaced by NICE guideline NG10.

    Evidence summary
    Published
    11 March 2014